C4 Therapeutics, Inc.CCCCNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +38.75% | +58.75% | +138.17% | -46.17% | -26.90% |
| Gross Profit Growth | +46.59% | +117.26% | +138.17% | -35.12% | -15.60% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +41.48% | +37.86% | +3.51% | +3.19% | +4.22% |
| Weighted Average Shares Diluted Growth | +41.48% | +37.86% | +3.51% | +3.19% | +4.22% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +1968.20% | -73.71% | -40.97% | +84.92% | -36.74% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +12.93% | -7.13% | -19.79% | -22.19% | -29.40% |
| Book Value per Share Growth | -20.61% | -36.34% | -27.01% | -31.72% | -38.94% |
| Debt Growth | -7.05% | -7.35% | -7.68% | -8.03% | -8.39% |
| R&D Expense Growth | +12.32% | +6.98% | +20.14% | +10.29% | -18.37% |
| SG&A Expenses Growth | +11.73% | +20.53% | -9.31% | -9.57% | -24.20% |